Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 27;14:955–965. doi: 10.2147/OPTH.S241044

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Horner et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Number of intravitreal injections received by the whole cohort and by different RVO subgroups in each year.

(A) Percentage of patients (of the whole cohort) received X number of injections each year. (B) Year 1 RVO subgroup analyses: all subgroups shared similar frequency distribution, one CRVO patient (of neovascular glaucoma) needed 11 injections in Year 1. (C) Year 2 RVO subgroup analyses: BRVO and HRVO had the most numbers of patients not needing re-injections this year; and CRVO patients accounted for higher injection frequency. (D) Year 3 RVO subgroup analyses: 55% of BRVO needed no injections in Year 3, one HRVO patient had a severe recurrence and needed 10 injections.

Abbreviations: RVO, retinal vein occlusion; CRVO, central retinal vein occlusion; HRVO, hemi-retinal vein occlusion; BRVO, branch retinal vein occlusion.